Beaucare Medical Limited

beaucare.com

Beaucare Medical Ltd is the UK leader in care home supplies. Established in 1992, we offer a full range of nursing, janitorial, hygiene supplies, medical consumables and equipment to private care homes, hospitals and individuals. As a long standing supplier of 25 years, Beaucare prides itself on providing a knowledgeable sales and aftercare service to both trade customers and consumers alike.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

TARSIER PHARMA RAISES CAPITAL TO EXECUTE PHASE-3 CLINICAL TRIAL

Tarsier Pharma | August 28, 2021

news image

Tarsier Pharma, a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced it raised capital to execute a phase-3 clinical trial of its TRS01 program in the US and Europe. Strategic and new investors alongside existing investors participated in this transaction. Following a successful End of Phase II meeting with the FDA, the Company obtained all necessary regu...

Read More

Business Insights

TASLY PHARMACEUTICALS AND MAUNA KEA TECHNOLOGIES ANNOUNCE JOINT VENTURE AND LICENSING AGREEMENTS

Mauna Kea Technologies | July 12, 2022

news image

Mauna Kea Technologies inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy platform, and Tasly Pharmaceuticals announced the execution of an agreement to form a Joint Venture. Under terms of the agreement, Tasly and Mauna Kea will form a Joint Venture that will (i) commercialize selected Cellvizio indications in China, (ii) develop and commercialize Cellvizio globally in the fields of Neurology and Neurosurgery, and (iii) manufact...

Read More

Business Insights

MERCK ENTERS COLLABORATION AND OPTION TO LICENSE AGREEMENT WITH NERVIANO MEDICAL SCIENCES TO DEVELOP NEXT-GENERATION PARP1 SELECTIVE INHIBITOR

Merck | September 22, 2022

news image

Merck, a leading science and technology company, announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l. for the next-generation highly selective and brain-penetrant PARP1 inhibitor, NMS-293. NMS-293 has strong potential in combination with a wide variety of DNA-damaging agents, including systemic or targeted chemotherapy or with DNA damage response inhibitors, in numerous tumor types. NMS-293 is in early clinical development for the treatment of patients ...

Read More

Pharmacy Market

BC PLATFORMS ADDS JAPANS MITSUBISHI SPACE SOFTWARE TO ITS GLOBAL DATA NETWORK

BC Platforms | February 21, 2022

news image

BC Platforms (BCP), a global leader in healthcare data management and analytics, announced a new data partnership with Japan's Mitsubishi Space Software Co. Ltd. (Mitsubishi), one of the country's oldest bioinformatics companies. The collaboration, which provides secure access to Mitsubishi's cancer specific cohort of 8,000 patients, will accelerate the provision of cancer genetic data analysis services to medical institutions for cancer research. As part of the collab...

Read More
news image

Pharmacy Market

TARSIER PHARMA RAISES CAPITAL TO EXECUTE PHASE-3 CLINICAL TRIAL

Tarsier Pharma | August 28, 2021

Tarsier Pharma, a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced it raised capital to execute a phase-3 clinical trial of its TRS01 program in the US and Europe. Strategic and new investors alongside existing investors participated in this transaction. Following a successful End of Phase II meeting with the FDA, the Company obtained all necessary regu...

Read More
news image

Business Insights

TASLY PHARMACEUTICALS AND MAUNA KEA TECHNOLOGIES ANNOUNCE JOINT VENTURE AND LICENSING AGREEMENTS

Mauna Kea Technologies | July 12, 2022

Mauna Kea Technologies inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy platform, and Tasly Pharmaceuticals announced the execution of an agreement to form a Joint Venture. Under terms of the agreement, Tasly and Mauna Kea will form a Joint Venture that will (i) commercialize selected Cellvizio indications in China, (ii) develop and commercialize Cellvizio globally in the fields of Neurology and Neurosurgery, and (iii) manufact...

Read More
news image

Business Insights

MERCK ENTERS COLLABORATION AND OPTION TO LICENSE AGREEMENT WITH NERVIANO MEDICAL SCIENCES TO DEVELOP NEXT-GENERATION PARP1 SELECTIVE INHIBITOR

Merck | September 22, 2022

Merck, a leading science and technology company, announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l. for the next-generation highly selective and brain-penetrant PARP1 inhibitor, NMS-293. NMS-293 has strong potential in combination with a wide variety of DNA-damaging agents, including systemic or targeted chemotherapy or with DNA damage response inhibitors, in numerous tumor types. NMS-293 is in early clinical development for the treatment of patients ...

Read More
news image

Pharmacy Market

BC PLATFORMS ADDS JAPANS MITSUBISHI SPACE SOFTWARE TO ITS GLOBAL DATA NETWORK

BC Platforms | February 21, 2022

BC Platforms (BCP), a global leader in healthcare data management and analytics, announced a new data partnership with Japan's Mitsubishi Space Software Co. Ltd. (Mitsubishi), one of the country's oldest bioinformatics companies. The collaboration, which provides secure access to Mitsubishi's cancer specific cohort of 8,000 patients, will accelerate the provision of cancer genetic data analysis services to medical institutions for cancer research. As part of the collab...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us